Details

Autor(en) / Beteiligte

• Chen, M.K.
• Qin, Z.K.
• Zhou, F.J.
• Han, H.
• Liu, Z.W.
• Li, Y.H.
• Yao, K.
• Hou, G.L.
• Ye, Y.L.
• Zhang, Z.L.
• Tu, H.
• Zhang, X.Q.
• Lu, K.S.
• Yang, Z.W.

Titel

Intra-Arterial Chemotherapy is Reliable in Preventing High-Risk Superficial Bladder Cancer from Recurrence and Progression

Ist Teil von

• Journal of chemotherapy (Florence), 2009-12, Vol.21 (6), p.681-686

Ort / Verlag

Firenze: Taylor & Francis

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• The purpose of this prospective study was to evaluate the therapeutic effects of intra-arterial chemotherapy in preventing high-risk superficial bladder cancer from recurrence and progression. From May 2003 to December 2007, 52 patients were divided randomly into 2 groups. Twenty-five patients were given intra-arterial chemotherapy with gemcitabine and cisplatin, and 27 patients received intravesical instillation with epirubicin. After 6-67 months of follow-up (median, 40 months), the overall recurrence-free rates of the intra-arterial chemotherapy and intravesical instillation groups were 83.3% and 33.4%, respectively (p=0.001 log rank). Tumor progression was not found in the intra-arterial chemotherapy group while 7 patients in the intravesical instillation group had tumor progression. The overall tumor progression free rates were 100% and 58.5%, respectively (p=0.009 log rank). The patients with functional bladders were 100% and 81.5% in the intra-arterial chemotherapy and intravesical instillation groups after 67 months of follow-up, respectively. In conclusion, intra-arterial chemotherapy is more effective than intravesical instillation in preventing high-risk superficial bladder cancer from recurrence and progression.